STOCK TITAN

AEye launches $50M at-the-market stock program

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

AEye, Inc. (LIDR) established a new at-the-market equity program by entering into an At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners, allowing the company to offer and sell common stock with an aggregate offering price of up to $50,000,000 from time to time under its effective shelf registration statement on Form S-3. A prospectus supplement dated September 15, 2026 covers these shares. Net proceeds are intended for working capital and general corporate purposes, including research and development, expansion of commercial and business development activities in aerospace, defense and infrastructure markets, capital expenditures, and general and administrative expenses. A.G.P. will act as sales agent for ATM transactions on or through The Nasdaq Capital Market and other permitted methods, while Craig-Hallum Capital Group LLC will serve as financial advisor.

Positive

  • None.

Negative

  • None.

Filing Explained

The new ATM agreement creates up to $50 million of potential equity capacity, but no completed sales are disclosed; dilution depends on future issuance.

The September 15 Form 8-K reports an executed agreement allowing AEye to sell up to $50 million of common stock, not a completed stock sale; if shares are later issued, total shares would increase and existing holders’ percentage ownership would decrease.

This is an at-the-market arrangement, meaning shares may be sold gradually at prevailing market prices, but AEye is not required to sell any shares and may suspend sales. The filing therefore establishes potential issuance capacity rather than proceeds received or dilution already incurred.

AEye terminated its prior September 12, 2024 sales agreement when the new agreement was executed, without an early termination penalty. The new agreement ends when the registered shares are sold, the agreement is terminated, or the 36-month anniversary of the September 15 prospectus supplement is reached, whichever occurs first.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 1.02 Termination of a Material Definitive Agreement Business
A significant contract was terminated, which may affect business operations or revenue.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
ATM aggregate offering capacity $50,000,000 Maximum aggregate offering price of Placement Shares under the At Market Issuance Sales Agreement
Sales agent commission rate Up to 3.0% of gross proceeds Cash commission payable to A.G.P. on sales of Placement Shares
Financial advisor fee Up to 1.0% of gross proceeds Advisory fee payable to Craig-Hallum on each sale of Placement Shares
A.G.P. implementation expense cap $50,000 Maximum reimbursement for execution and implementation costs of the Sales Agreement
Per due diligence session expense cap $5,000 Cap per due diligence update session reimbursable to A.G.P.
Annual due diligence expense cap $15,000 per fiscal year Maximum aggregate reimbursable due diligence expenses per fiscal year
ATM program duration 36 months Program ends at the 36-month anniversary of the prospectus supplement filing if not earlier terminated or fully sold
at-the-market offering financial
"Sales of Placement Shares, if any, will be made by any method permitted by law deemed to be an “at-the-market offering”"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
shelf registration statement regulatory
"The Placement Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"The Company filed a prospectus supplement dated September 15, 2026, with the Securities and Exchange Commission"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
gross proceeds financial
"The Company will pay A.G.P. a cash commission rate up to 3.0% of the gross proceeds"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
due diligence financial
"up to $5,000 per due diligence update session thereafter pursuant to the terms of the Sales Agreement"
Due diligence is the careful investigation and analysis someone conducts before making a decision, such as investing money or entering into an agreement. It’s like researching thoroughly before buying a used car to ensure it’s in good condition; this helps prevent surprises and makes informed choices. For investors, due diligence reduces risk by verifying details and understanding what they’re getting into.
Offering Type ATM
Use of Proceeds Working capital and general corporate purposes, including research and development, expansion of commercial and business development activities in aerospace, defense and infrastructure markets, capital expenditures, and general and administrative expenses.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity offering did AEye, Inc. (LIDR) announce in this 8-K?

AEye, Inc. entered into an At Market Issuance Sales Agreement with A.G.P./Alliance Global Partners to offer and sell its common stock with an aggregate offering price of up to $50,000,000 from time to time under its Form S-3 shelf registration.

How will AEye, Inc. (LIDR) use the proceeds from the $50 million ATM program?

AEye plans to use net proceeds for working capital and general corporate purposes, which may include research and development, expansion of commercial and business development activities in aerospace, defense and infrastructure markets, capital expenditures, and general and administrative expenses.

What fees will AEye, Inc. (LIDR) pay under the new At Market Issuance Sales Agreement?

AEye will pay A.G.P. a cash commission rate of up to 3.0% of gross proceeds from sales of shares. It will also pay Craig-Hallum advisory fees of up to 1.0% of gross proceeds from each sale, plus specified reimbursable expenses to A.G.P.

When does the AEye, Inc. (LIDR) ATM offering terminate?

The offering will terminate on the earliest of the 36-month anniversary of the prospectus supplement filing, the sale of all Placement Shares, or termination of the Sales Agreement by either AEye or A.G.P. as provided in that agreement.

What happened to AEye, Inc.’s prior At Market Issuance Sales Agreement?

In connection with the new Sales Agreement, AEye and A.G.P. mutually agreed to terminate the Prior Sales Agreement dated September 12, 2024, effective upon execution of the new agreement. AEye did not incur any early termination penalties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001818644 0001818644 2026-09-15 2026-09-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 15, 2026

 

AEYE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39699   37-1827430
(State or other jurisdiction   (Commission File Number)   (IRS Employer Identification No.)
of incorporation)        

 

4670 Willow Road, Suite 125, Pleasanton, California   94588
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (925) 400-4366

 

   
(Former Name or Former Address, if Changed Since Last Report)  

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share LIDR The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 1.01.Entry into a Material Definitive Agreement.

 

On September 15, 2026, AEye, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”). In accordance with the terms of the Sales Agreement, the Company may offer and sell from time to time through A.G.P., acting as sales agent, the Company’s common stock having an aggregate offering price of up to $50,000,000 (the “Placement Shares”). The Placement Shares will be issued pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333-296038). The Company filed a prospectus supplement dated September 15, 2026, with the Securities and Exchange Commission in connection with the offer and sale of the Placement Shares.

The Company intends to use the net proceeds from the sale of the Placement Shares to fund working capital and general corporate purposes to support its future growth, which may include research and development, expansion of its commercial and business development activities, including in the aerospace and defense and infrastructure markets, capital expenditures, and general and administrative expenses.

Under the terms and subject to the conditions of the Sales Agreement, the Company will set the parameters for the sale of shares, including the number or dollar amount of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number or dollar amount of Placement Shares that may be sold in any one trading day and any minimum price below which sales may not be made. Sales of Placement Shares, if any, will be made by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through The Nasdaq Capital Market, the trading market for the Company’s common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices, and/or any other method permitted by law. The Company is under no obligation to sell any Placement Shares under the Sales Agreement and may at any time suspend offers and sales of Placement Shares under the Sales Agreement.

The Company will pay A.G.P. a cash commission rate up to 3.0% of the gross proceeds from the sale of Placement Shares sold pursuant to the Sales Agreement. The Company will also reimburse A.G.P. for certain specified expenses in connection with this offering, including reasonable out-of-pocket costs and expenses, including legal fees and related expenses, in an amount not to exceed (a) $50,000 in connection with the execution and implementation of the Sales Agreement and (b) up to $5,000 per due diligence update session thereafter pursuant to the terms of the Sales Agreement, not to exceed $15,000 per fiscal year, in connection with any periodic due diligence review conducted by A.G.P. or its representatives in connection with the offering. In connection with the offering, Craig-Hallum Capital Group LLC (“Craig-Hallum”) is acting as a financial advisor, for which the Company will pay Craig-Hallum advisory fees up to 1.0% of the gross proceeds from each sale of Placement Shares pursuant to the Sales Agreement.

The offering of the Placement Shares pursuant to the Sales Agreement will terminate upon the earliest of (i) the 36-month anniversary of the filing of the prospectus supplement registering the Placement Shares, (ii) the sale of all of the Placement Shares, or (iii) termination of the Sales Agreement as provided therein. The Company and A.G.P. may each terminate the Sales Agreement at any time upon 30 days’ prior notice.

The foregoing description of the Sales Agreement is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is attached hereto as Exhibit 1.1, and is incorporated herein in its entirety by reference. The representations, warranties, and covenants contained in the Sales Agreement are made only for purposes of such agreement and as of the specific date, are solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties. The legal opinion relating to the Placement Shares is filed as Exhibit 5.1 hereto.

 

This Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy any shares of common stock in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

 

   

 

 

Item 1.02.Termination of a Material Definitive Agreement.

On September 15, 2026, in connection with its entry into the Sales Agreement described in Item 1.01 above, the Company and A.G.P. mutually agreed to terminate, effective upon the execution of the Sales Agreement, the At Market Issuance Sales Agreement, dated September 12, 2024, between the Company and A.G.P., as amended (the “Prior Sales Agreement”), pursuant to which the Company was entitled to offer and sell shares of its common stock from time to time through A.G.P., acting as sales agent. The Company did not incur any early termination penalties in connection with the termination of the Prior Sales Agreement.

Item 9.01.Financial Statement and Exhibits.

 

(d)       Exhibits.

 

 Exhibit NumberDescription
   
1.1At Market Issuance Sales Agreement by and between AEye, Inc. and A.G.P./Alliance Global Partners, dated September 15, 2026.

 

5.1Opinion of Allen Overy Shearman Sterling US LLP.

 

23.1Consent of Allen Overy Shearman Sterling US LLP (included in Exhibit 5.1).

 

104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

   

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    AEye, Inc.
     
Dated: September 15, 2026    
    By: /s/ Siraj Husain
    Name: Siraj Husain
    Title: Vice President, General Counsel and Corporate Secretary

 

 

 

 

 

 

 

 

   

 

 

Filing Exhibits & Attachments

5 documents

Keep reading